Jeil Pharma Holdings Inc (KRX:002620)
South Korea · Delayed Price · Currency is KRW 8,490.00
-100.00 (-1.16%)
At close: Apr 2, 2026
Jeil Pharma Holdings Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 633,700 | 769,968 | 794,714 | 787,256 | 756,633 |
Other Revenue | 23,914 | 9,855 | 9,329 | 5,708 | 5,935 |
| 657,614 | 779,822 | 804,043 | 792,965 | 762,568 | |
Revenue Growth (YoY) | -15.67% | -3.01% | 1.40% | 3.99% | 0.07% |
Cost of Revenue | 404,116 | 573,301 | 589,459 | 612,482 | 582,061 |
Gross Profit | 253,498 | 206,521 | 214,584 | 180,483 | 180,507 |
Selling, General & Admin | 167,068 | 158,715 | 146,364 | 146,465 | 149,808 |
Research & Development | 45,203 | 38,950 | 46,038 | 41,566 | 39,673 |
Other Operating Expenses | 1,682 | 20,719 | 1,363 | - | - |
Operating Expenses | 214,512 | 217,702 | 193,664 | 188,031 | 189,482 |
Operating Income | 38,986 | -11,181 | 20,920 | -7,548 | -8,975 |
Interest Expense | -7,494 | -8,875 | -10,672 | -5,952 | -3,289 |
Interest & Investment Income | 1,948 | 2,456 | 4,119 | 508.95 | 256.81 |
Earnings From Equity Investments | 808.35 | - | - | - | 2,516 |
Currency Exchange Gain (Loss) | -140.06 | 3,019 | -169.48 | 314.8 | 816.09 |
Other Non Operating Income (Expenses) | 69.9 | -7,435 | -2,492 | 856.19 | -2,864 |
EBT Excluding Unusual Items | 34,178 | -22,016 | 11,706 | -11,820 | -11,539 |
Impairment of Goodwill | - | -44,862 | -28,604 | -78,335 | -17,014 |
Gain (Loss) on Sale of Investments | 5,379 | 5,907 | 2,923 | 7,127 | 20,876 |
Gain (Loss) on Sale of Assets | 12.08 | 7.97 | 0.53 | 23.98 | 1,930 |
Asset Writedown | -204.32 | -662.52 | -7.42 | -856.39 | -382 |
Pretax Income | 39,365 | -61,626 | -13,982 | -83,861 | -6,129 |
Income Tax Expense | 4,718 | 4,765 | -740.82 | -715.62 | 6,741 |
Earnings From Continuing Operations | 34,647 | -66,391 | -13,241 | -83,145 | -12,870 |
Net Income to Company | 34,647 | -66,391 | -13,241 | -83,145 | -12,870 |
Minority Interest in Earnings | -20,012 | 15,232 | -3,009 | 8,589 | 9,388 |
Net Income | 14,635 | -51,159 | -16,250 | -74,556 | -3,482 |
Net Income to Common | 14,635 | -51,159 | -16,250 | -74,556 | -3,482 |
Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 |
Shares Change (YoY) | 0.05% | -0.01% | - | - | - |
EPS (Basic) | 953.00 | -3333.00 | -1058.54 | -4856.70 | -226.85 |
EPS (Diluted) | 953.00 | -3333.00 | -1059.00 | -4857.00 | -227.00 |
Free Cash Flow | -7,893 | 202.38 | -10,638 | -32,717 | -10,284 |
Free Cash Flow Per Share | -513.98 | 13.19 | -692.99 | -2131.27 | -669.95 |
Dividend Per Share | - | - | 50.000 | 50.000 | 65.000 |
Dividend Growth | - | - | - | -23.08% | -7.14% |
Gross Margin | 38.55% | 26.48% | 26.69% | 22.76% | 23.67% |
Operating Margin | 5.93% | -1.43% | 2.60% | -0.95% | -1.18% |
Profit Margin | 2.23% | -6.56% | -2.02% | -9.40% | -0.46% |
Free Cash Flow Margin | -1.20% | 0.03% | -1.32% | -4.13% | -1.35% |
EBITDA | 53,935 | 2,918 | 33,476 | 3,357 | 8.31 |
EBITDA Margin | 8.20% | 0.37% | 4.16% | 0.42% | 0.00% |
D&A For EBITDA | 14,949 | 14,099 | 12,556 | 10,905 | 8,983 |
EBIT | 38,986 | -11,181 | 20,920 | -7,548 | -8,975 |
EBIT Margin | 5.93% | -1.43% | 2.60% | -0.95% | -1.18% |
Effective Tax Rate | 11.99% | - | - | - | - |
Advertising Expenses | 7,974 | 9,597 | 5,929 | 6,228 | 8,742 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.